2 reports

HENCE, PEG-FILGRASTIM HAS A DISTINCT ADVANTAGE IN TERMS OF PATIENT SAFETY AGAINST FILGRASTIM.

  • Biochemical
  • Europe
  • World
  • Roche Group
  • Sandoz Inc.

s Neupogen (filgrastim), which was originally licensed in 1991.

  • Biochemical
  • United States
  • Life Technologies Corporation
  • Sigma-Aldrich
  • Thermo Fisher Scientific, Inc.